Reckitt Benckiser Group Plc News - RKT

FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC...

Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action...

Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of...

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

- New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy...

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC...

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC...

$8 Million Private Placement Announcement Sends Biotech Flying

Usually when a publicly traded company announces some sort of equity offering, it can be viewed as a dilutive event, thus having a negative effect...

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

BERKELEY HEIGHTS, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC...

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing...

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from...

US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat

In Tuesday’s pre-market trading, U.S. index futures are pointing to a decline, reflecting...

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC...

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

BERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC...

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Reckitt Benckiser Group Plc (RKT)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

RKT News

FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

$8 Million Private Placement Announcement Sends Biotech Flying

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

RKT Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Reckitt Benckiser Group Plc (RKT) News

Reckitt Benckiser Group Plc (RKT)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

RKT News

FeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

$8 Million Private Placement Announcement Sends Biotech Flying

Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results

Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit

RKT Discussion

Your Recent History